TipRanks Black Friday Sale
- Claim 60% off TipRanks Premium for the data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Orthocell Ltd ( (AU:OCC) ) just unveiled an update.
Orthocell Ltd has announced the increasing adoption of its product, Remplir™, among Australian urologists for nerve-sparing prostate cancer surgeries, with approximately 100 surgeries conducted nationwide. This application aims to reduce complications such as erectile dysfunction and urinary incontinence, presenting a significant commercial opportunity for the company. Orthocell plans to expand its U.S. market from $1.6 billion to $2 billion by investing in further research and establishing a commercialization advisory board to support a targeted U.S. launch. The company is also compiling clinical data from initial procedures in Australia to bolster its scientific foundation for international market launches.
The most recent analyst rating on (AU:OCC) stock is a Hold with a A$1.00 price target. To see the full list of analyst forecasts on Orthocell Ltd stock, see the AU:OCC Stock Forecast page.
More about Orthocell Ltd
Orthocell Ltd is a company operating in the medical industry, focusing on peripheral nerve protection and repair. Its primary product, Remplir™, is used in surgeries to reduce post-surgical complications, particularly in nerve-sparing prostate cancer surgeries. The company is targeting a significant market expansion in the U.S., leveraging its innovative applications in the field.
Average Trading Volume: 807,037
Technical Sentiment Signal: Buy
Current Market Cap: A$277.9M
For a thorough assessment of OCC stock, go to TipRanks’ Stock Analysis page.